Effects of Policosanol (10 mg/d) Versus Aspirin (100 mg/d) in Patients With Intermittent Claudication: A 10-Week, Randomized, Comparative Study
Antiplatelet therapy, including aspirin, is recommended to lower the vascular risk in patients with intermittent claudication. Policosanol has increased walking distances in these patients, probably because of its antiplatelet effects, but the effect of shorter treatment has not been studied. This d...
Gespeichert in:
| Veröffentlicht in: | Angiology 2008-06, Vol.59 (3), p.269-277 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 277 |
|---|---|
| container_issue | 3 |
| container_start_page | 269 |
| container_title | Angiology |
| container_volume | 59 |
| creator | Illnait, José Castaño, Gladys Alvarez, Ernesto Fernández, Lilia Mas, Rosa Mendoza, Sarahí Gamez, Rafael |
| description | Antiplatelet therapy, including aspirin, is recommended to lower the vascular risk in patients with intermittent claudication. Policosanol has increased walking distances in these patients, probably because of its antiplatelet effects, but the effect of shorter treatment has not been studied. This double-blind study compared the effects of policosanol 10 mg/d and aspirin 100 mg/d for 10 weeks on walking distances in claudicants. Thirty-nine patients were randomized to policosanol or aspirin. Walking distances on a treadmill were assessed before and after treatment. Policosanol significantly increased the initial and absolute claudication distances, while aspirin changed neither variable. Policosanol, not aspirin, significantly lowered serum low-density lipoprotein-cholesterol and total cholesterol while raising high-density lipoprotein-cholesterol. In conclusion, treatments of policosanol, not aspirin, for 10 weeks significantly increased walking distances, but modestly, in contrast with previous results. Therefore, the duration of treatments at the doses tested was too short for meaningful effects on the treadmill test. |
| doi_str_mv | 10.1177/0003319707306963 |
| format | Article |
| fullrecord | <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1177_0003319707306963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0003319707306963</sage_id><sourcerecordid>10.1177_0003319707306963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-778cfe66885d0d6ae8cb91495efb2fbdda6b5d71cd2901816f165379b283f8e3</originalsourceid><addsrcrecordid>eNp1kFFLwzAUhYMobk7ffZI8KqwuWdYk9W2MqYOBQ4d7LGmTzMy2KUkrzD_hXzZjE0Hw6XLud86FewC4xOgWY8YGCCFCcMIQI4gmlByBLk5GKMIxGx2D7g5HO94BZ95vgowxoqeggznhHBHeBV9TrVXeeGg1XNjC5NaLyhbwGiNYrgfyBr4q51sPx742zlQ78EOCWojGqCrEV6Z5g7OqUa40TRNWcFKIVpo8GGx1B8cQo2il1HsfPotK2tJ8KtmHE1vWwgXPh4IvTSu35-BEi8Kri8PsgeX9dDl5jOZPD7PJeB7lhKImYoznWlHKeSyRpELxPEvwKImVzoY6k1LQLJYM53KYIMwx1ZjGhCXZkBPNFekBtD-bO-u9UzqtnSmF26YYpbtq07_VhsjVPlK3Wankb-DQZTBEe4MXa5VubOuq8MH_B78Br4N_vA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effects of Policosanol (10 mg/d) Versus Aspirin (100 mg/d) in Patients With Intermittent Claudication: A 10-Week, Randomized, Comparative Study</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Illnait, José ; Castaño, Gladys ; Alvarez, Ernesto ; Fernández, Lilia ; Mas, Rosa ; Mendoza, Sarahí ; Gamez, Rafael</creator><creatorcontrib>Illnait, José ; Castaño, Gladys ; Alvarez, Ernesto ; Fernández, Lilia ; Mas, Rosa ; Mendoza, Sarahí ; Gamez, Rafael</creatorcontrib><description>Antiplatelet therapy, including aspirin, is recommended to lower the vascular risk in patients with intermittent claudication. Policosanol has increased walking distances in these patients, probably because of its antiplatelet effects, but the effect of shorter treatment has not been studied. This double-blind study compared the effects of policosanol 10 mg/d and aspirin 100 mg/d for 10 weeks on walking distances in claudicants. Thirty-nine patients were randomized to policosanol or aspirin. Walking distances on a treadmill were assessed before and after treatment. Policosanol significantly increased the initial and absolute claudication distances, while aspirin changed neither variable. Policosanol, not aspirin, significantly lowered serum low-density lipoprotein-cholesterol and total cholesterol while raising high-density lipoprotein-cholesterol. In conclusion, treatments of policosanol, not aspirin, for 10 weeks significantly increased walking distances, but modestly, in contrast with previous results. Therefore, the duration of treatments at the doses tested was too short for meaningful effects on the treadmill test.</description><identifier>ISSN: 0003-3197</identifier><identifier>EISSN: 1940-1574</identifier><identifier>DOI: 10.1177/0003319707306963</identifier><identifier>PMID: 18388038</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adult ; Aged ; Aspirin - administration & dosage ; Aspirin - adverse effects ; Double-Blind Method ; Drug Administration Schedule ; Exercise Test ; Fatty Alcohols - administration & dosage ; Fatty Alcohols - adverse effects ; Female ; Humans ; Intermittent Claudication - blood ; Intermittent Claudication - drug therapy ; Intermittent Claudication - physiopathology ; Lipids - blood ; Male ; Middle Aged ; Platelet Aggregation Inhibitors - administration & dosage ; Platelet Aggregation Inhibitors - adverse effects ; Recovery of Function ; Treatment Outcome ; Walking</subject><ispartof>Angiology, 2008-06, Vol.59 (3), p.269-277</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-778cfe66885d0d6ae8cb91495efb2fbdda6b5d71cd2901816f165379b283f8e3</citedby><cites>FETCH-LOGICAL-c360t-778cfe66885d0d6ae8cb91495efb2fbdda6b5d71cd2901816f165379b283f8e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0003319707306963$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0003319707306963$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,778,782,21806,27911,27912,43608,43609</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18388038$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Illnait, José</creatorcontrib><creatorcontrib>Castaño, Gladys</creatorcontrib><creatorcontrib>Alvarez, Ernesto</creatorcontrib><creatorcontrib>Fernández, Lilia</creatorcontrib><creatorcontrib>Mas, Rosa</creatorcontrib><creatorcontrib>Mendoza, Sarahí</creatorcontrib><creatorcontrib>Gamez, Rafael</creatorcontrib><title>Effects of Policosanol (10 mg/d) Versus Aspirin (100 mg/d) in Patients With Intermittent Claudication: A 10-Week, Randomized, Comparative Study</title><title>Angiology</title><addtitle>Angiology</addtitle><description>Antiplatelet therapy, including aspirin, is recommended to lower the vascular risk in patients with intermittent claudication. Policosanol has increased walking distances in these patients, probably because of its antiplatelet effects, but the effect of shorter treatment has not been studied. This double-blind study compared the effects of policosanol 10 mg/d and aspirin 100 mg/d for 10 weeks on walking distances in claudicants. Thirty-nine patients were randomized to policosanol or aspirin. Walking distances on a treadmill were assessed before and after treatment. Policosanol significantly increased the initial and absolute claudication distances, while aspirin changed neither variable. Policosanol, not aspirin, significantly lowered serum low-density lipoprotein-cholesterol and total cholesterol while raising high-density lipoprotein-cholesterol. In conclusion, treatments of policosanol, not aspirin, for 10 weeks significantly increased walking distances, but modestly, in contrast with previous results. Therefore, the duration of treatments at the doses tested was too short for meaningful effects on the treadmill test.</description><subject>Adult</subject><subject>Aged</subject><subject>Aspirin - administration & dosage</subject><subject>Aspirin - adverse effects</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Exercise Test</subject><subject>Fatty Alcohols - administration & dosage</subject><subject>Fatty Alcohols - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Intermittent Claudication - blood</subject><subject>Intermittent Claudication - drug therapy</subject><subject>Intermittent Claudication - physiopathology</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Platelet Aggregation Inhibitors - administration & dosage</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Recovery of Function</subject><subject>Treatment Outcome</subject><subject>Walking</subject><issn>0003-3197</issn><issn>1940-1574</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kFFLwzAUhYMobk7ffZI8KqwuWdYk9W2MqYOBQ4d7LGmTzMy2KUkrzD_hXzZjE0Hw6XLud86FewC4xOgWY8YGCCFCcMIQI4gmlByBLk5GKMIxGx2D7g5HO94BZ95vgowxoqeggznhHBHeBV9TrVXeeGg1XNjC5NaLyhbwGiNYrgfyBr4q51sPx742zlQ78EOCWojGqCrEV6Z5g7OqUa40TRNWcFKIVpo8GGx1B8cQo2il1HsfPotK2tJ8KtmHE1vWwgXPh4IvTSu35-BEi8Kri8PsgeX9dDl5jOZPD7PJeB7lhKImYoznWlHKeSyRpELxPEvwKImVzoY6k1LQLJYM53KYIMwx1ZjGhCXZkBPNFekBtD-bO-u9UzqtnSmF26YYpbtq07_VhsjVPlK3Wankb-DQZTBEe4MXa5VubOuq8MH_B78Br4N_vA</recordid><startdate>20080601</startdate><enddate>20080601</enddate><creator>Illnait, José</creator><creator>Castaño, Gladys</creator><creator>Alvarez, Ernesto</creator><creator>Fernández, Lilia</creator><creator>Mas, Rosa</creator><creator>Mendoza, Sarahí</creator><creator>Gamez, Rafael</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20080601</creationdate><title>Effects of Policosanol (10 mg/d) Versus Aspirin (100 mg/d) in Patients With Intermittent Claudication: A 10-Week, Randomized, Comparative Study</title><author>Illnait, José ; Castaño, Gladys ; Alvarez, Ernesto ; Fernández, Lilia ; Mas, Rosa ; Mendoza, Sarahí ; Gamez, Rafael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-778cfe66885d0d6ae8cb91495efb2fbdda6b5d71cd2901816f165379b283f8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aspirin - administration & dosage</topic><topic>Aspirin - adverse effects</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Exercise Test</topic><topic>Fatty Alcohols - administration & dosage</topic><topic>Fatty Alcohols - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Intermittent Claudication - blood</topic><topic>Intermittent Claudication - drug therapy</topic><topic>Intermittent Claudication - physiopathology</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Platelet Aggregation Inhibitors - administration & dosage</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Recovery of Function</topic><topic>Treatment Outcome</topic><topic>Walking</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Illnait, José</creatorcontrib><creatorcontrib>Castaño, Gladys</creatorcontrib><creatorcontrib>Alvarez, Ernesto</creatorcontrib><creatorcontrib>Fernández, Lilia</creatorcontrib><creatorcontrib>Mas, Rosa</creatorcontrib><creatorcontrib>Mendoza, Sarahí</creatorcontrib><creatorcontrib>Gamez, Rafael</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Angiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Illnait, José</au><au>Castaño, Gladys</au><au>Alvarez, Ernesto</au><au>Fernández, Lilia</au><au>Mas, Rosa</au><au>Mendoza, Sarahí</au><au>Gamez, Rafael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Policosanol (10 mg/d) Versus Aspirin (100 mg/d) in Patients With Intermittent Claudication: A 10-Week, Randomized, Comparative Study</atitle><jtitle>Angiology</jtitle><addtitle>Angiology</addtitle><date>2008-06-01</date><risdate>2008</risdate><volume>59</volume><issue>3</issue><spage>269</spage><epage>277</epage><pages>269-277</pages><issn>0003-3197</issn><eissn>1940-1574</eissn><abstract>Antiplatelet therapy, including aspirin, is recommended to lower the vascular risk in patients with intermittent claudication. Policosanol has increased walking distances in these patients, probably because of its antiplatelet effects, but the effect of shorter treatment has not been studied. This double-blind study compared the effects of policosanol 10 mg/d and aspirin 100 mg/d for 10 weeks on walking distances in claudicants. Thirty-nine patients were randomized to policosanol or aspirin. Walking distances on a treadmill were assessed before and after treatment. Policosanol significantly increased the initial and absolute claudication distances, while aspirin changed neither variable. Policosanol, not aspirin, significantly lowered serum low-density lipoprotein-cholesterol and total cholesterol while raising high-density lipoprotein-cholesterol. In conclusion, treatments of policosanol, not aspirin, for 10 weeks significantly increased walking distances, but modestly, in contrast with previous results. Therefore, the duration of treatments at the doses tested was too short for meaningful effects on the treadmill test.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>18388038</pmid><doi>10.1177/0003319707306963</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-3197 |
| ispartof | Angiology, 2008-06, Vol.59 (3), p.269-277 |
| issn | 0003-3197 1940-1574 |
| language | eng |
| recordid | cdi_crossref_primary_10_1177_0003319707306963 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Adult Aged Aspirin - administration & dosage Aspirin - adverse effects Double-Blind Method Drug Administration Schedule Exercise Test Fatty Alcohols - administration & dosage Fatty Alcohols - adverse effects Female Humans Intermittent Claudication - blood Intermittent Claudication - drug therapy Intermittent Claudication - physiopathology Lipids - blood Male Middle Aged Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Recovery of Function Treatment Outcome Walking |
| title | Effects of Policosanol (10 mg/d) Versus Aspirin (100 mg/d) in Patients With Intermittent Claudication: A 10-Week, Randomized, Comparative Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T10%3A29%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Policosanol%20(10%20mg/d)%20Versus%20Aspirin%20(100%20mg/d)%20in%20Patients%20With%20Intermittent%20Claudication:%20A%2010-Week,%20Randomized,%20Comparative%20Study&rft.jtitle=Angiology&rft.au=Illnait,%20Jos%C3%A9&rft.date=2008-06-01&rft.volume=59&rft.issue=3&rft.spage=269&rft.epage=277&rft.pages=269-277&rft.issn=0003-3197&rft.eissn=1940-1574&rft_id=info:doi/10.1177/0003319707306963&rft_dat=%3Csage_cross%3E10.1177_0003319707306963%3C/sage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18388038&rft_sage_id=10.1177_0003319707306963&rfr_iscdi=true |